Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 15;14:8361. doi: 10.1038/s41467-023-43780-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a, b Relative cell number after treatment of cells with A485 and A486 for 6 days, as determined by high content microscopy (n = 3 independent experiments, means ± SD). c ChIP-seq clusters of p300 in enhancers in RH4 cells. d L2FC of mRNA in RH4 cells treated with 10 μM A485 for 6 h. Genes are ranked according to p300 cluster decile (n = 1 independent experiment, box plots of median and quartiles, whiskers showing 1.5 × inter-quartile ranges). e Upper panels, dose-response curves of RH5 cells treated with A485 and dCBP1 over 5 days as determined by Incucyte microscopy (n = 2 independent experiments, means ± SD). Middle panels, schemes depicting the mechanism of action for both drugs. Lower panels, plots comparing RNA-seq data from cells treated with A485 and dCBP1 for 6 h (n = 1 independent experiment, Welch’s t-test). f Degree of downregulation of indicated gene classes after CBP/p300 inhibition (n = 1 independent experiment; box plots of median and quartiles, whiskers showing 1.5 × inter-quartile ranges). g TPM values of MYOD1 and MYCN after drug treatment in RH4 and RH5 (MYCN-amplified) cells. h GSEA comparing the degree of downregulation of core regulatory transcription factor genes and genes within P3F enhancer TADs upon P3F silencing via shRNA. i Western blot detection of indicated proteins from indicated cells after dCBP1 treatment for 24 h. One representative blot from n = 3 is shown. j mRNA levels in indicated cells after 24 h of dCBP1 treatment. L2FC to DMSO is shown (n = 3 independent experiments, means ± SD, Tukey’s multiple comparisons test). k Relative cell number and percentage of dead cells in indicated cells after dCBP1 treatment for 6 days (n = 3 independent experiments, means ± SD). l Cell cycle analysis of indicated cells after dCBP1 treatment for 24 h (n = 3 independent experiments, means ± SD). m H3K27ac ChIP-seq data for the PIPOX locus in RH4 cells treated with DMSO or dCBP1. Delta track shows control subtracted from dCBP1. n H3K27ac ChIP-seq signal in RH4 cells before and after treatment with dCBP1 for 6 h. Source data are provided as a Source Data file.